application) Recent advances in our understanding of the molecular basis of renal disease provide the potential for developing molecular based strategies for therapy. They include the cloning of the """"""""minor"""""""" collagens and the discovery of their role in Goodpasture's and Alport syndrome, the cloning of transport proteins in the kidney that are involved with Gitelman's and Bartter's syndromes, and the identification of the genetic defect associated with PKD 1 and 2. Recent reports of linkage in families with FSGS and IgA nephropathy and the identification of quantitative trait loci that affect the phenotypic expression of cyst formation in the PKD mouse have provided new insights into the molecular basis of renal pathogenesis. The evidence from angiotensinogen knock-outs and quantitative """"""""knock-in"""""""" experiments has provided proof of concept and molecular evidence that additive genetic traits may control long-term blood pressure regulation by the kidney. How these findings will translate into better therapies for patients remains to be determined but is clearly a long-term goal. This application requests partial support for the costs of a conference that will help facilitate entry of investigators into this area in renal research entitled, """"""""Frontiers in Nephrology, Gene Therapy."""""""" This conference, to be held June 4-6 in Beaver Creek Colorado, will be a satellite meeting that immediately follows the American Society of Gene Therapy in Denver, Colorado. The goal of the conference is to bring leaders in gene therapy and molecular genetics together with trainees and junior faculty to provide an environment that will promote interaction and facilitate future research in this field. The hope is to bring the two fields together to address issues of importance to the renal community. The meeting will be held in a single room conference in the style of a Keystone or Gordon Conference and poster sessions will provide additional opportunities for the attendees. The conference will be advertised in Science, Nature Medicine, Kidney International, and Journal of Molecular Therapy. In addition, announcements will be made at the ASN in Miami and brochures will be provided both there and will be sent to program directors as well.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Conference (R13)
Project #
1R13DK058334-01
Application #
6191419
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Scherbenske, M James
Project Start
2000-06-01
Project End
2001-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
1
Fiscal Year
2000
Total Cost
$25,000
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029